Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery
- 1 July 2017
- journal article
- practice guideline
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 78 (3) , 162-175
Abstract
No abstract availableThis publication has 71 references indexed in Scilit:
- Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease ProgressionThyroid®, 2013
- The Impact of Distant Metastases at Presentation on Prognosis in Patients with Differentiated Carcinoma of the Thyroid GlandThyroid®, 2012
- Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid CancerNew England Journal of Medicine, 2012
- Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid CancerNew England Journal of Medicine, 2012
- Delayed Initial Radioactive Iodine Therapy Resulted in Poor Survival in Patients with Metastatic Differentiated Thyroid Carcinoma: A Retrospective Statistical Analysis of 198 CasesJournal of Nuclear Medicine, 2011
- The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid CancerThyroid®, 2009
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcomeEndocrine-Related Cancer, 2007
- Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patientsClinical Endocrinology, 2006
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumEuropean Journal of Endocrinology, 2006